Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients

被引:462
作者
Curkendall, SM [1 ]
DeLuise, C [1 ]
Jones, JK [1 ]
Lanes, S [1 ]
Stang, MR [1 ]
Goehring, E [1 ]
She, DW [1 ]
机构
[1] Cerner Hlth Insights, Vienna, VA 22182 USA
关键词
chronic obstructive pulmonary disease; cardiovascular diseases; incidence; prevalence; cohort studies; mortality; comorbidity; Saskatchewan;
D O I
10.1016/j.annepidem.2005.04.008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: To measure prevalence, incidence, and mortality of cardiovascular outcomes among persons with chronic obstructive pulmonary disease (COPD) and to assess the extent these outcomes differ from persons without COPD. METHODS: Retrospective cohort study in longitudinal health care databases maintained by the government of Saskatchewan, Canada. Subjects were persons age 40 years or older who were diagnosed with COPD during 1997-2000 and who received two or more prescriptions for bronchodilators within 6 months of diagnosis. Each subject was matched by age and sex to two controls without COPD or asthma. RESULTS: Of COPD patients (n = 11,493), 54% were male, and 74% were 65 years or older. Prevalence of all cardiovascular diseases was higher in the COPD group than in the comparison group. After adjusting for cardiovascular risk, odds ratios of prevalence were: arrhythmia 1.76 (confidence interval [CI]: 1.641.89), angina 1.61 (CI: 1.47-1.76), acute myocardial infarction 1.61 (CI: 1.43-1.81), congestive heart failure 3.84(CI: 3.56-4.14), stroke 1.11 (CI: 1.02-1.21), pulmonary embolism 5.46 (CI: 4.25-7.02). Risk of hospitalization due to each cardiovascular cause was elevated in the COPD group. The risk ratio for cardiovascular mortality was 2.07 (CI: 1.82-2.36) and all cause mortality was 2.82 (CI: 2.61-3.05). CONCLUSIONS: Persons with diagnosed and treated COPD are at increased risk for hospitalizations and deaths due to cardiovascular diseases.
引用
收藏
页码:63 / 70
页数:8
相关论文
共 24 条
  • [1] Systemic effects of chronic obstructive pulmonary disease
    Agustí, AGN
    Noguera, A
    Sauleda, J
    Sala, E
    Pons, J
    Busquets, X
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (02) : 347 - 360
  • [2] [Anonymous], 2002, DAT FIL DOC NAT HLTH
  • [3] Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease
    Baillard, C
    Boussarsar, M
    Fosse, JP
    Girou, E
    Le Toumelin, P
    Cracco, C
    Jaber, S
    Cohen, Y
    Brochard, L
    [J]. INTENSIVE CARE MEDICINE, 2003, 29 (04) : 584 - 589
  • [4] Statin use and the risk of breast cancer
    Beck, P
    Wysowski, DK
    Downey, W
    Butler-Jones, D
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) : 280 - 285
  • [5] BERKOW R, 1999, MERCK MANUAL DIAGNOS, P570
  • [6] Curkendall SM, 2004, J CLIN PSYCHIAT, V65, P715
  • [7] Downey W, 2000, PHARMACOEPIDEMIOLOGY, V3rd, P325
  • [8] LUNG-FUNCTION AND RISK OF MYOCARDIAL-INFARCTION AND SUDDEN CARDIAC DEATH
    FRIEDMAN, GD
    ARTHUR, MS
    KLATSKY, L
    SIEGELAUB, AB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (20) : 1071 - 1075
  • [9] Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure
    Gutthann, SP
    Rodriguez, LAG
    Raiford, DS
    Oliart, AD
    Romeu, JR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (21) : 2433 - 2439
  • [10] HABBICK B, 1995, CAN MED ASSOC J, V153, P1437